Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

Y Guo, D Jones, JL Palmer, A Forman, SR Dakhil… - Supportive care in …, 2014 - Springer
Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …
被引用次数：124 相关文章
[HTML] nih.gov

[HTML][HTML] Oral Alpha-Lipoic Acid to Prevent Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Trial

Y Guo, D Jones, JL Palmer, A Forman… - Supportive care in …, 2014 - ncbi.nlm.nih.gov
Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

Y Guo, D Jones, JL Palmer, A Forman… - Supportive Care in …, 2014 - search.proquest.com
Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor in cancer
treatment and may cause pain and irreversible function loss in cancer survivors. We tested …

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

Y Guo, D Jones, JL Palmer, A Forman… - Supportive Care in …, 2014 - go.gale.com
Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.

Y Guo, D Jones, J Palmer, A Forman… - Supportive Care in …, 2014 - search.ebscohost.com
Objectives: Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting
factor in cancer treatment and may cause pain and irreversible function loss in cancer …

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

Y Guo, D Jones, JL Palmer, A Forman, SR Dakhil… - 2014 - pubmed.ncbi.nlm.nih.gov
Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …
[PDF] academia.edu

[PDF][PDF] Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

Y Guo, D Jones, JL Palmer, A Forman… - Support Care …, 2014 - academia.edu
Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.

Y Guo, D Jones, JL Palmer, A Forman… - Supportive Care in …, 2013 - europepmc.org
Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial

Y Guo, D Jones, JL Palmer… - … Care in Cancer, 2014 - mdanderson.elsevierpure.com
Objectives: Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting
factor in cancer treatment and may cause pain and irreversible function loss in cancer …
[PDF] researchgate.net

[PDF][PDF] Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

Y Guo, D Jones, JL Palmer, A Forman, SR Dakhil… - 2013 - researchgate.net
Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …